Fastest growing therapy area driven by handful of big hitters

22 May 2023
globaldata-logo-big

Industry analyst GlobalData has outlined the driving factors in hematology, identifying Ultomiris (ravulizumab), Hemlibra (emicizumab) and Vafseo (vadadustat) as key products in this category.

There has been a significant increase in revenues for hematology products in recent periods, making this the fastest-growing therapy area for the second year running.

Alexion Pharmaceuticals’ Ultomiris, Genentech’s Hemlibra, and Akebia Therapeutics’ (Nasdaq: AKBA) Vafseo (vadadustat) are likely to be responsible for much of the growth going forward.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology